# US 2013/0295064 A1 · Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295064 A1
- Document ID: US20130295064A1
- Status: Published application
- Kind: A1
- Application number: 13/879,350
- Filed: 2011-10-14
- Published: 2013-11-07
- Earliest claimed: 2010-10-14
- Assignees: University of Central Florida Research Foundation, Inc.
- Inventors: Dinender Singla
- Web page: https://patentgrep.com/patent/US20130295064A1

## CPC

- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2506/1315: from cardiomyocytes
- C12N 2506/45: from artificially induced pluripotent stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Cardiac myocyte differentiation reported thus far is from iPS cells generated from mice and human fibroblasts. iPS cells from cardiac or ventricular specific cell types are generated herein having the potential to repair and regenerate infarcted myocardium. The cells were transduced with four sternness factors and reprogrammed them into iPS cells. These cardiac iPS cells were able to differentiate into beating cardiac myocytes, formed cardiac-specific structures, and positively stained for cardiac specific proteins. Transplanted cells also significantly inhibited apoptosis and fibrosis and improved cardiac function.

## Claims

### Claim 1

A method of repairing or regenerating damaged cardiac tissue due to cardiac dysfunction in a subject in need thereof comprising administering to the subject cardiac induced pluripotent stem cells, derived from a cardiac or ventricular cell type, that stably express one or more inserted stem-cell like factors, wherein the stem-cell like factors comprise Oct3/4, KIf4, Sox2 and c-Myc or any combination thereof; and the cardiac or ventricular cell type is a cardiofibroblast, cardiomyoblast or H9c2 cardiomyoblast cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cardiac dysfunction is a cardiac ischemia/reperfusion event or a congenital heart defect.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ischemia/reperfusion event is myocardial infarction, myocardial ischemia, myocardial reperfusion, subendocardial ischemia, Takayasu's arteritis, atrial fibrillation, hemorrhagic strokes, an ischemia/reperfusion event occurring during cardiac surgery where a heart lung machine is used, an ischemia/reperfusion event occurring during coronary artery bypass, or ischemia/reperfusion event occurring during the preservation of an organ for transplant, or wherein the congenital heart defect is hypoplasia or pentalogy of Cantrell,

### Claim 4 (depends on 1)

The method of claim 1, wherein the cardiac induced pluripotent stem cells are administered in two equal intra-myocardial injections.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cardiac induced pluripotent stem cells are administered in a peri-infarct region.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cardiac or ventricular cells are obtained from autologous, allogeneic, or syngeneic source.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cDNAs of the stem-cell like factors Oct3/4 and KIf4 are in separate vectors when inserted into the cardiac or ventricular cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the stem-cell like factors are expressed from a vector comprising the KIf4-2A sequence and the Oct-3/4 sequence in the same reading frame that is fused to a Sox2 sequence with a stop codon to form a Oct-3/4- KIf4-2A-Sox2 vector.

### Claim 9 (depends on 8)

The method of claim 8, wherein the vector comprises the Oct-3/4- KIf4-2A-Sox2 sequences inserted into a pCX-EGFP vector.

### Claim 10 (depends on 9)

The method of claim 9, further comprising inserting c-Myc cDNA into the vector.

### Claim 11 (depends on 8)

The method of claim 8, wherein the vector comprises the Oct-3/4- KIf4-2A-Sox2 sequences inserted into a pCX-c-Myc vector.

### Claim 12 (depends on 7)

The method of claim 7, wherein a vector is pBS-2A.

### Claim 13

Cardiac induced pluripotent stem cells, comprising a cardiac or ventricular cell type having a stable vector that expresses at least one stem-cell like factor, wherein the vector comprises the sequence of at least one of Oct3/4, KIf4, Sox2 or c-Myc.

### Claim 14 (depends on 13)

The stem cells of claim 13, wherein the sequences for KIf4, Sox2 and Oct3/4 are operably linked through the self-cleaving 2A sequence of foot-and-mouth disease virus.

### Claim 15 (depends on 13)

The stem cells of claim 13, wherein the cardiac or ventricular cell type are human or rodent cells that are obtained from an autologous, allogeneic, or syngeneic source, and wherein the cardiac or ventricular cell type is a cardiofibroblast, cardiomyoblast or H9c2 cardiomyoblast cell.
